Please login to the form below

Not currently logged in
Email:
Password:

Label change for Lilly's Livalo

The US Food and Drug Administration has said Eli Lilly & Company can update the label of cholesterol drug Livalo to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir

The US Food and Drug Administration (FDA) has said Eli Lilly & Company can update the label of cholesterol drug Livalo (pitavastatin) to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir.

The decision follows a study investigating the effects on patients when co-administered both treatments.

Data from the study demonstrated that there was no significant impact on the blood levels of participants, with minimal interaction between the two drugs.

"Livalo showed minimal drug-drug interactions with a common antiretroviral therapy HIV patients need to fight the disease," said Dr Judith Aberg, director of Virology, Bellevue Hospital Center and director, Division of Infectious Diseases and Immunology, NYU School of Medicine. "For a patient population that is taking multiple medications, this is exciting news."

Drugs to lower cholesterol, such as Livalo, are often prescribed to patients with HIV, with elevated cholesterol a complication associated with both the virus itself and antiretroviral therapies.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics